钠-葡萄糖共转运蛋白2抑制剂对糖尿病相关眼病的影响
Effects of sodium-glucose cotransporter 2 inhibitors on ocular diseases in patients with diabetes melli-tus
王雪 1张真稳1
作者信息
- 1. 扬州大学附属苏北人民医院,扬州 225000
- 折叠
摘要
眼是糖尿病主要损害的靶器官之一,糖尿病相关眼病是一组严重影响患者视觉质量乃至致盲的疾病.目前的临床治疗大多适用于眼病晚期,亟需相关防治眼病发生发展的药物.钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是用于降低糖尿病患者高血糖的新型口服药物,在糖尿病相关性心血管和肾脏疾病已表现出高度有益作用.目前,利用SGLT2i降低血糖同时防治糖尿病相关眼部疾病也成为一个新的研究领域.本文主要综述了 SGLT2i在糖尿病相关眼部疾病的研究进展.
Abstract
The eye is one of the major target organs damaged by diabetes,and diabetes-related eye diseases are a group of diseases that seriously affect the quality of vision of patients and even cause blind-ness.Most of the current clinical treatments are applicable to the advanced stages of eye disease,and there is an urgent need for drugs to prevent the development of eye disease.Sodium-Glucose Transporter 2 Inhibi-tors(SGLT2i)are novel oral drugs used to reduce hyperglycaemia in diabetic patients,and have shown highly beneficial effects in diabetes-associated cardiovascular and renal diseases.Currently,the use of SGLT2i to lower blood glucose while preventing diabetes-associated eye diseases has also become a new area of research.This article mainly reviews the research progress of SGLT2i in diabetes-related eye diseases.
关键词
钠-葡萄糖共转运蛋白2抑制剂/糖尿病性视网膜病变/糖尿病性白内障/糖尿病性角膜病变Key words
Sodium-Glucose Transporter 2 Inhibitors/Diabetic Retinopathy/Diabetic Cataract/Dia-betic Keratopathy引用本文复制引用
基金项目
江苏省中医药科技发展计划(YB2020087)
国家自然科学基金(82374100)
出版年
2024
NETL
NSTL
万方数据